GHRP-2 vs GHRP-6: evidence, status and structure
A side-by-side look at GHRP-2 and GHRP-6, using the data on each VALREXA profile. Neither comparison is a recommendation.
Key differences
- Both sit at the same evidence level: Early human.
- Both have the same U.S. status category: Not FDA-approved.
| GHRP-2 | GHRP-6 | |
| Research class | Endocrine & Growth | Endocrine & Growth |
| Human evidence | Early human | Early human |
| U.S. status | Not FDA-approved | Not FDA-approved |
| 2026 compounding decision | — | — |
| Amino acids | 6 | 6 |
| Molecular weight | ~817.98 Da | ~873.0 Da |
| Formula | Varies by form | Varies by form |
| Sequence | — | — |
| Research period | 1984 | 1984 |
| Safety summary | Not FDA-approved for human therapeutic use in the United States. | Not FDA-approved for human therapeutic use in the United States. |
How they differ
Both are synthetic hexapeptides (six amino acids) that act on the ghrelin receptor to stimulate growth hormone release. They come from the same 1980s line of research. GHRP-6 was the earlier compound and is generally reported to stimulate appetite more strongly; GHRP-2 is reported to be more potent at releasing growth hormone. Neither is FDA-approved.
What each one is
GHRP-2: Synthetic growth-hormone secretagogue that acts at the ghrelin receptor. Molecular weight, sequence, research history, human evidence and regulatory status.
GHRP-6: Synthetic ghrelin-receptor agonist studied in endocrine physiology. Molecular weight, sequence, research history, human evidence and regulatory status.
Educational reference only. Nothing here is medical advice, a treatment recommendation, or dosing or sourcing guidance. Report an error.